IAM Patent 1000 2021

Patents are essential business commodities and knowing how to obtain, enforce and monetise them has become mission critical. The IAM Patent 1000 has firmly established itself as the definitive ‘go-to’ resource for those seeking to identify world-class, private practice patent expertise.

France

France is increasingly seen as an attractive venue for pharmaceutical multinationals to assert their patent rights: many have interpreted a significant victory for Eli Lilly against generics producer Fresenius Kabi at the Paris Court of First Instance in 2020 as a sign that the tide has turned in originators’ favour....

Read more

France is increasingly seen as an attractive venue for pharmaceutical multinationals to assert their patent rights: many have interpreted a significant victory for Eli Lilly against generics producer Fresenius Kabi at the Paris Court of First Instance in 2020 as a sign that the tide has turned in originators’ favour. It’s not all good news, however: some commentators suggest that the country may become a hotspot for SPC nullity actions following Merck’s recent defeat in a long-running SPC dispute. Reforms to the prosecution process introduced in 2019 via President Macron’s Action Plan for Business Growth and Transformation continue to bed down; while the IP community awaits clarification on the fate of the UPC, especially with regard to the division that was previously destined to be in London.

Show less

Get unlimited access to all IAM content